Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

NCT03739606 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03739606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
October 20, 2020
Completion date
October 20, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute leukemia, chronic myelogenous leukemia, bcr-abl1 positive, hairy cell leukemia, interleukin-3 receptor subunit alpha positive, recurrent acute lymphoblastic leukemia, recurrent blastic plasmacytoid dendritic cell neoplasm, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent hematologic malignancy, recurrent hodgkin lymphoma, refractory acute lymphoblastic leukemia, refractory blastic plasmacytoid dendritic cell neoplasm, refractory hematologic malignancy, refractory hodgkin lymphoma, systemic mastocytosis